End Of Fosamax Patent Heralds Payday For Generics

Law360, New York (February 7, 2008, 12:00 AM EST) -- Patent protection for Merck & Co.'s Fosamax expired on Wednesday, giving other pharmaceutical companies the thumbs-up to start marketing generic versions of the popular osteoporosis drug.

Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals both said they had received approval from the U.S. Food and Drug Administration to market generic versions of Fosamax.

Teva announced Wednesday that it would begin marketing the drug in 5 mg, 10 mg, 35 mg, 40 mg and 70 mg tablets. Shipment of the product will begin immediately, the company said....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.